SINTX Technologies Issues Business Update Following Strategic Realignment, Leadership Expansion, and SiNAPTIC Acquisition

Core Insights - SINTX Technologies is undergoing a strategic transformation following the acquisition of SiNAPTIC, focusing on accelerating growth in the medical device sector over the next 12 to 24 months [1][2][3] Business Update - The company has made significant progress in its commercialization strategy and has streamlined operations to focus on high-margin, high-growth opportunities in orthopedic and surgical markets [1][4] - SINTX has successfully implanted over 50,000 spinal interbody devices and aims to leverage its differentiated orthopedic and spine technologies for revenue and margin growth [3][4] Leadership and Team Expansion - The acquisition of SiNAPTIC has enhanced SINTX's leadership team with experienced MedTech innovators, improving its commercial capabilities [4][5] - Key appointments include Bryan Scheer, M.D. as Chairman of the Clinical Advisory Board, and Lisa Marie Del Re as Chief Commercial Officer, among others [5] Strategic Focus and Operations - The company has divested non-core assets, including the sale of its Maryland-based subsidiary, to enhance strategic focus [5] - SINTX has exited low-margin OEM manufacturing, which contributed to a slight decrease in revenue during Q2 2025, reflecting a purposeful transition towards more profitable operations [6] Future Growth Strategy - SINTX plans to continue building its scientific foundation and intellectual property portfolio, with recent advancements in composite implant design and antimicrobial ceramics [7][11] - The company is committed to transparency with shareholders as it moves towards commercialization [7]